Skip to main content
Erschienen in: International Journal of Colorectal Disease 4/2019

26.01.2019 | Original Article

Associations between multiple immunosuppressive treatments before surgery and surgical morbidity in patients with ulcerative colitis during the era of biologics

verfasst von: Motoi Uchino, Hiroki Ikeuchi, Toshihiro Bando, Teruhiro Chohno, Hirofumi Sasaki, Yuki Horio, Ryuichi Kuwahara, Tomohiro Minagawa, Yoshiko Goto, Kaoru Ichiki, Kazuhiko Nakajima, Yoshiko Takahashi, Takashi Ueda, Yoshio Takesue

Erschienen in: International Journal of Colorectal Disease | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It is unclear whether immunomodulators or biologics, with the exception of corticosteroids, can be risk factors for postoperative infectious complications of ulcerative colitis (UC). Moreover, many immunosuppressive therapies including some biologics are used mainly to treat UC, and many patients are on multi-agent immunosuppressive therapy at the time of surgery. Therefore, we evaluated the influence of pre-operative multiple immunosuppressive agents on the occurrence of surgical site infection (SSI) in UC during the era of biologics.

Methods

We reviewed surveillance data from 301 patients who underwent surgery between January 2015 and April 2018. The incidences of SSI and possible risk factors among patients receiving different immunosuppressive therapies were compared and analyzed.

Results

The incidence of incisional SSI was 6.6%, and that of organ/space SSI was 7.0%. Doses of corticosteroids were significantly decreased because of the recent shift toward the use of biologics. The types and numbers of immunosuppressive agents did not significantly correlate with each incidence. Age ≥ 65 years (odds ratio (OR) 3.0), total prednisolone dose ≥ 9000 mg (OR 2.7), and perioperative blood transfusion (OR 3.6) were shown to be independent risk factors for incisional SSI, whereas duration of surgery ≥ 252 min (OR 3.8), urgent/emergent surgery (OR 2.9), and perioperative blood transfusion (OR 2.6) were identified as independent risk factors for organ/space SSI.

Conclusions

Although no correlation between pre-operative immunosuppressive therapies, except for corticosteroids, was found, selection bias may have occurred due to treatment before surgery. However, biologics, calcineurin inhibitors, and thiopurines did not affect surgical morbidity in UC.
Literatur
1.
Zurück zum Zitat Nelson R, Liao C, Fichera A, Rubin DT, Pekow J (2014) Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 20:14–20CrossRefPubMed Nelson R, Liao C, Fichera A, Rubin DT, Pekow J (2014) Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis 20:14–20CrossRefPubMed
2.
Zurück zum Zitat Kimura H, Takahashi K, Futami K, Ikeuchi H, Tatsumi K, Watanabe K, Maeda K, Watadani Y, Nezu R, Kameyama H, Nakao S, Kurachi K, Hotokezaka M, Otsuka K, Watanabe T, Ozawa H (2016) Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan. Surg Today 46:930–938CrossRefPubMed Kimura H, Takahashi K, Futami K, Ikeuchi H, Tatsumi K, Watanabe K, Maeda K, Watadani Y, Nezu R, Kameyama H, Nakao S, Kurachi K, Hotokezaka M, Otsuka K, Watanabe T, Ozawa H (2016) Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan. Surg Today 46:930–938CrossRefPubMed
3.
Zurück zum Zitat Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962 discussion 962-963CrossRefPubMed Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962 discussion 962-963CrossRefPubMed
4.
Zurück zum Zitat Mor IJ, Vogel JD, da Luz MA et al (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202–1207 discussion 1207-1210CrossRefPubMed Mor IJ, Vogel JD, da Luz MA et al (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202–1207 discussion 1207-1210CrossRefPubMed
5.
Zurück zum Zitat Yang Z, Wu Q, Wu K et al (2010) Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 31:486–492CrossRefPubMed Yang Z, Wu Q, Wu K et al (2010) Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 31:486–492CrossRefPubMed
6.
Zurück zum Zitat Uchino M, Ikeuchi H, Matsuoka H, Tsuchida T, Tomita N, Takesue Y (2010) Risk factors associated with surgical site infection after ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 53:143–149CrossRefPubMed Uchino M, Ikeuchi H, Matsuoka H, Tsuchida T, Tomita N, Takesue Y (2010) Risk factors associated with surgical site infection after ileal pouch-anal anastomosis in ulcerative colitis. Dis Colon Rectum 53:143–149CrossRefPubMed
7.
Zurück zum Zitat Uchino M, Ikeuchi H, Bando T, Hirose K, Hirata A, Chohno T, Sasaki H, Takahashi Y, Takesue Y, Hida N, Hori K, Nakamura S (2015) Does pre-operative multiple immunosuppressive therapy associate with surgical site infection in surgery for ulcerative colitis. Digestion 92:121–129CrossRefPubMed Uchino M, Ikeuchi H, Bando T, Hirose K, Hirata A, Chohno T, Sasaki H, Takahashi Y, Takesue Y, Hida N, Hori K, Nakamura S (2015) Does pre-operative multiple immunosuppressive therapy associate with surgical site infection in surgery for ulcerative colitis. Digestion 92:121–129CrossRefPubMed
8.
Zurück zum Zitat Chohno T, Uchino M, Sasaki H, Bando T, Takesue Y, Ikeuchi H (2018) Associations between the prognostic nutritional index and morbidity/mortality during intestinal resection in patients with ulcerative colitis. World J Surg 42:1949–1959CrossRefPubMed Chohno T, Uchino M, Sasaki H, Bando T, Takesue Y, Ikeuchi H (2018) Associations between the prognostic nutritional index and morbidity/mortality during intestinal resection in patients with ulcerative colitis. World J Surg 42:1949–1959CrossRefPubMed
9.
Zurück zum Zitat Heuschen UA, Hinz U, Allemeyer EH, Autschbach F, Stern J, Lucas M, Herfarth C, Heuschen G (2002) Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg 235:207–216CrossRefPubMedPubMedCentral Heuschen UA, Hinz U, Allemeyer EH, Autschbach F, Stern J, Lucas M, Herfarth C, Heuschen G (2002) Risk factors for ileoanal J pouch-related septic complications in ulcerative colitis and familial adenomatous polyposis. Ann Surg 235:207–216CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Truelove S, Jewell D (1974) Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1:1067–1070CrossRefPubMed Truelove S, Jewell D (1974) Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1:1067–1070CrossRefPubMed
12.
Zurück zum Zitat Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG, Banerjee SN, Edwards JR, Tolson JS, Henderson TS, Hughes JM, National Nosocomial Infections Surveillance System (1991) Surgical wound infection rates by wound class, operative procedure, and patient risk index. National nosocomial infections surveillance system. Am J Med 91:152S–158SCrossRefPubMed Culver DH, Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG, Banerjee SN, Edwards JR, Tolson JS, Henderson TS, Hughes JM, National Nosocomial Infections Surveillance System (1991) Surgical wound infection rates by wound class, operative procedure, and patient risk index. National nosocomial infections surveillance system. Am J Med 91:152S–158SCrossRefPubMed
13.
Zurück zum Zitat Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606–608CrossRefPubMed Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG (1992) CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 13:606–608CrossRefPubMed
14.
Zurück zum Zitat Gu J, Remsi FH, Shen B et al (2013) Operative strategy modifies risk if pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-α therapy. Dis Colon Rectum 56:1243–1252CrossRefPubMed Gu J, Remsi FH, Shen B et al (2013) Operative strategy modifies risk if pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-α therapy. Dis Colon Rectum 56:1243–1252CrossRefPubMed
15.
Zurück zum Zitat Eshuis EJ, Al Saady RL, Stokkers PCF et al (2013) Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohns Colitis 7:142–149CrossRefPubMed Eshuis EJ, Al Saady RL, Stokkers PCF et al (2013) Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis. J Crohns Colitis 7:142–149CrossRefPubMed
16.
Zurück zum Zitat Uchino M, Ikeuchi H, Matsuoka H, Bando T, Ichiki K, Nakajima K, Tomita N, Takesue Y (2013) Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis. Int J Color Dis 28:1295–1306CrossRef Uchino M, Ikeuchi H, Matsuoka H, Bando T, Ichiki K, Nakajima K, Tomita N, Takesue Y (2013) Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis. Int J Color Dis 28:1295–1306CrossRef
17.
Zurück zum Zitat Kwag SJ, Kim JG, Kang WK, Lee JK, Oh ST (2014) The nutritional risk is an independent factor for postoperative morbidity in surgery for colorectal cancer. Ann Surg Treat Res 86:206–211CrossRefPubMedPubMedCentral Kwag SJ, Kim JG, Kang WK, Lee JK, Oh ST (2014) The nutritional risk is an independent factor for postoperative morbidity in surgery for colorectal cancer. Ann Surg Treat Res 86:206–211CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Isik O, Kaya E, Dundar HZ, Sarkut P (2015) Surgical site infection: re-assessment of the risk factors. Chirurgia (Bucur) 110:457–461 Isik O, Kaya E, Dundar HZ, Sarkut P (2015) Surgical site infection: re-assessment of the risk factors. Chirurgia (Bucur) 110:457–461
19.
Zurück zum Zitat Kolbe L, Kligman AM, Schreiner V, Stoudemayer T (2001) Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 7:73–77CrossRefPubMed Kolbe L, Kligman AM, Schreiner V, Stoudemayer T (2001) Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 7:73–77CrossRefPubMed
20.
Zurück zum Zitat Keenan JE, Speicher PJ, Thacker JK et al (2014) The preventive surgical site infection bundle in colorectal surgery: an effective approach to surgical site infection reduction and health care cost savings. JAMA Surg 149:1045–1052CrossRefPubMed Keenan JE, Speicher PJ, Thacker JK et al (2014) The preventive surgical site infection bundle in colorectal surgery: an effective approach to surgical site infection reduction and health care cost savings. JAMA Surg 149:1045–1052CrossRefPubMed
21.
Zurück zum Zitat Lutfiyya W, Parsons D, Breen J (2012) A colorectal “care bundle” to reduce surgical site infections in colorectal surgeries: a single center experience. Perm J 16:10–16PubMedPubMedCentral Lutfiyya W, Parsons D, Breen J (2012) A colorectal “care bundle” to reduce surgical site infections in colorectal surgeries: a single center experience. Perm J 16:10–16PubMedPubMedCentral
22.
Zurück zum Zitat Waits SA, Fritze D, Banerjee M, Zhang W, Kubus J, Englesbe MJ, Campbell DA Jr, Hendren S (2014) Developing an argument for bundled interventions to reduce surgical site infection in colorectal surgery. Surgery 155:602–606CrossRefPubMed Waits SA, Fritze D, Banerjee M, Zhang W, Kubus J, Englesbe MJ, Campbell DA Jr, Hendren S (2014) Developing an argument for bundled interventions to reduce surgical site infection in colorectal surgery. Surgery 155:602–606CrossRefPubMed
23.
Zurück zum Zitat Cima R, Dankbar E, Lovely J, Pendlimari R, Aronhalt K, Nehring S, Hyke R, Tyndale D, Rogers J, Quast L, Colorectal Surgical Site Infection Reduction Team (2013) Colorectal surgery surgical site infection reduction program: a national surgical quality improvement program–driven multidisciplinary single-institution experience. J Am Coll Surg 216:23–33CrossRefPubMed Cima R, Dankbar E, Lovely J, Pendlimari R, Aronhalt K, Nehring S, Hyke R, Tyndale D, Rogers J, Quast L, Colorectal Surgical Site Infection Reduction Team (2013) Colorectal surgery surgical site infection reduction program: a national surgical quality improvement program–driven multidisciplinary single-institution experience. J Am Coll Surg 216:23–33CrossRefPubMed
24.
25.
Zurück zum Zitat Cornillie F, Shealy D, D'Haens G, Geboes K, van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15:463–473CrossRefPubMed Cornillie F, Shealy D, D'Haens G, Geboes K, van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15:463–473CrossRefPubMed
Metadaten
Titel
Associations between multiple immunosuppressive treatments before surgery and surgical morbidity in patients with ulcerative colitis during the era of biologics
verfasst von
Motoi Uchino
Hiroki Ikeuchi
Toshihiro Bando
Teruhiro Chohno
Hirofumi Sasaki
Yuki Horio
Ryuichi Kuwahara
Tomohiro Minagawa
Yoshiko Goto
Kaoru Ichiki
Kazuhiko Nakajima
Yoshiko Takahashi
Takashi Ueda
Yoshio Takesue
Publikationsdatum
26.01.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 4/2019
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-019-03253-x

Weitere Artikel der Ausgabe 4/2019

International Journal of Colorectal Disease 4/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.